Form 4: Apogee CMO Sells Shares Under Pre-Set Plan

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 2,725 shares of common stock for $37.78 per share under a Rule 10b5-1 trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), disposed of 2,725 shares of common stock.
• The transaction occurred on August 6, 2025, at a price of $37.78 per share.
• Following this sale, Mr. Dambkowski beneficially owns 236,273 shares of Apogee Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 21, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the fact that it was conducted under a Rule 10b5-1 trading plan indicates it was a pre-scheduled event, not a reaction to new information or a change in management's outlook on the company's prospects. This mitigates any negative sentiment typically associated with insider selling.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the Rule 10b5-1 plan mitigates this.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice for corporate executives to manage their equity holdings and diversify assets while complying with insider trading regulations. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned nature under a 10b5-1 plan suggests it is not indicative of a change in company fundamentals or management confidence.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider stock sale under a Rule 10b5-1 plan. Such transactions are typically for personal financial planning or diversification and are not usually indicative of a change in the company's fundamental outlook or a signal for investors to buy or sell. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' recommendation.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, Carl Dambkowski, Chief Medical Officer, 10b5-1 Plan